508
Participants
Start Date
June 16, 2020
Primary Completion Date
August 7, 2026
Study Completion Date
August 7, 2026
Bimekizumab
Subjects will receive bimekizumab at prespecified time-points.
As0014 50020, Duncansville
As0014 50015, Hagerstown
As0014 50059, Ormond Beach
As0014 50056, Sarasota
As0014 50016, St Louis
As0014 50057, Dallas
As0014 50052, Phoenix
As0014 50062, Glendale
As0014 50060, Upland
As0014 50055, Portland
As0014 40004, Brussels
As0014 40003, Genk
As0014 40001, Ghent
As0014 40006, Plovdiv
As0014 40007, Plovdiv
As0014 40005, Sofia
As0014 40008, Sofia
As0014 20040, Beijing
As0014 20021, Chengdu
As0014 20019, Guangzhou
As0014 20034, Hefei
As0014 20024, Nanjing
As0014 20018, Shanghai
As0014 20020, Shanghai
As0014 20026, Shanghai
As0014 20025, Wenzhou
As0014 40011, Brno
As0014 40009, Pardubice
As0014 40013, Prague
As0014 40014, Prague
As0014 40015, Prague
As0014 40016, Prague
As0014 40010, Uherské Hradiště
As0014 40012, Zlín
As0014 40018, Boulogne-Billancourt
As0014 40022, Limoges
As0014 40025, Berlin
As0014 40029, Hamburg
As0014 40024, Hanover
As0014 40027, Herne
As0014 40078, Leipzig
As0014 40026, Ratingen
As0014 40032, Debrecen
As0014 40031, Szeged
As0014 40033, Székesfehérvár
As0014 20035, Bunkyō City
As0014 20030, Chūōku
As0014 20039, Iruma-gun
As0014 20036, Kawachi-Nagano
As0014 20045, Kita-gun
As0014 20065, Kitakyushu
As0014 20037, Osaka
As0014 20084, Saga
As0014 20048, Saitama
As0014 20031, Sapporo
As0014 20032, Suita
As0014 40034, Amsterdam
As0014 40038, Elblag
As0014 40042, Krakow
As0014 40037, Lublin
As0014 40044, Poznan
As0014 40040, Torun
As0014 40041, Warsaw
As0014 40039, Wroclaw
As0014 40043, Wroclaw
As0014 40045, A Coruña
As0014 40046, Córdoba
As0014 40048, Santiago de Compostela
As0014 40049, Seville
As0014 40052, Ankara
As0014 40053, Ankara
As0014 40050, Istanbul
As0014 40057, Edinburgh
As0014 40056, Leeds
As0014 40055, Norwich
UCB Biopharma SRL
INDUSTRY